View in EDS

23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.

Saved in:
Bibliographic Details
Title: 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.
Authors: Benjamin JS; 23andMe, Inc. Therapeutics, South San Francisco, California., Jarret A; 23andMe, Inc. Therapeutics, South San Francisco, California., Bharill S; 23andMe, Inc. Therapeutics, South San Francisco, California., Fontanillas P; 23andMe, Inc. Research, Sunnyvale, California., Yadav S; 23andMe, Inc. Therapeutics, South San Francisco, California., Sen D; 23andMe, Inc. Therapeutics, South San Francisco, California., Ayupova D; 23andMe, Inc. Therapeutics, South San Francisco, California., Kellar D; 23andMe, Inc. Therapeutics, South San Francisco, California., Tilk S; 23andMe, Inc. Therapeutics, South San Francisco, California., Hom C; 23andMe, Inc. Therapeutics, South San Francisco, California., Bahrami Dizicheh Z; 23andMe, Inc. Therapeutics, South San Francisco, California., Chen IL; 23andMe, Inc. Therapeutics, South San Francisco, California., Diep AN; 23andMe, Inc. Therapeutics, South San Francisco, California., Shi S; 23andMe, Inc. Therapeutics, South San Francisco, California., Ivic N; Proteros Biostructures GmbH, Planegg, Germany., Bonnans C; 23andMe, Inc. Therapeutics, South San Francisco, California., Owyang A; 23andMe, Inc. Therapeutics, South San Francisco, California., Sood P; 23andMe, Inc. Therapeutics, South San Francisco, California., Fuh G; 23andMe, Inc. Therapeutics, South San Francisco, California., Schmidt M; 23andMe, Inc. Therapeutics, South San Francisco, California., Gerrick KY; 23andMe, Inc. Therapeutics, South San Francisco, California., Koenig P; 23andMe, Inc. Therapeutics, South San Francisco, California., Poggio M; 23andMe, Inc. Therapeutics, South San Francisco, California.
Corporate Authors: 23andMe Research Team
Source: Cancer research communications [Cancer Res Commun] 2025 Mar 01; Vol. 5 (3), pp. 476-495.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2767-9764
DOI:10.1158/2767-9764.CRC-24-0478